Evidence for the involvement of μ-opioid and δ-opioid receptors in the antinociceptive effect caused by oral administration of m-trifluoromethyl-diphenyl diselenide in mice.
Pain is one of the most prevalent conditions, which limits productivity and diminishes quality of life. This study examined the antinociceptive effects of m-trifluoromethyl-diphenyl diselenide [(m-CF3-C6H4Se)2] on behavioral models of pain in mice. The involvement of opioid receptors in (m-CF3-C6H4Se)2-induced antinociception was evaluated in the tail-immersion test. (m-CF3-C6H4Se)2 exhibited significant inhibition of nociception induced by capsaicin (1.6 μg/paw, intraplantarly) (10-100 mg/kg, orally), and acetic acid (1.6%, 10 ml/kg, intraperitoneally) (1-100 mg/kg, orally), and in tail-immersion (50-100 mg/kg) and hot-plate (10-100 mg/kg) tests. The antinociception caused by (m-CF3-C6H4Se)2 in the tail-immersion test was significantly attenuated by naloxone (a nonselective opioid antagonist, 1 mg/kg, subcutaneously), naloxonazine (a selective μ-opioid receptor antagonist, 35 mg/kg, subcutaneously), or naltrindole (a selective δ-opioid receptor antagonist, 5 mg/kg, intraperitoneally). In contrast, (m-CF3-C6H4Se)2-induced antinociception was not affected by treatment with nor-binaltorphimine (a selective κ-opioid receptor antagonist, 10 mg/kg, subcutaneously) or naloxone methiodide (a peripherally restricted opioid antagonist, 1 mg/kg, subcutaneously). These results indicate that (m-CF3-C6H4Se)2-elicited antinociception in different models of pain through mechanisms that seem to involve an interaction with the central opioid system, more specifically μ-opioid and δ-opioid receptors.
Brüning
César Augusto
CA
Laboratório de Síntese, Reatividade e Avaliação Farmacológica e Toxicológica de Organocalcogênios Centro de Ciências Naturais e Exatas, Universidade Federal de Santa Maria, Santa Maria, Rio Grande do Sul, Brazil.
Prigol
Marina
M
Roehrs
Juliano Alex
JA
Zeni
Gilson
G
Nogueira
Cristina Wayne
CW
D000284:Administration, Oral; D000701:Analgesics, Opioid / Q000494:pharmacology; D000818:Animals; D035841:Behavioral Research; D002211:Capsaicin / Q000008:administration & dosage; D051379:Mice; D017646:Organosilicon Compounds / Q000008:administration & dosage*; D010146:Pain / Q000503:physiopathology / Q000523:psychology; D010147:Pain Measurement; D017465:Receptors, Opioid, delta / Q000037:antagonists & inhibitors*; D017450:Receptors, Opioid, mu / Q000037:antagonists & inhibitors*; D018689:Sensory System Agents / Q000008:administration & dosage
D000701:Analgesics, Opioid; D017646:Organosilicon Compounds; D017465:Receptors, Opioid, delta; D017450:Receptors, Opioid, mu; D018689:Sensory System Agents; C546861:m-trifluoromethyl-diphenyl diselenide; D002211:Capsaicin